Nordic Capital acquires majority share in IntegriChain, the only fully integrated platform for pharma commercialization and market access
· Investment will accelerate IntegriChain’s ambitious growth targets and cement its status as a leading platform for pharma manufacturers to bring their science to market · Further strengthens Nordic Capital’s record as a leading healthcare and technology investorNordic Capital has signed an agreement to acquire a majority share in IntegriChain, a leading provider of pharmaceutical technology, data, consulting, and outsourcing solutions designed to improve how life sciences products reach customers. IntegriChain delivers pharma's only fully integrated platform for commercialization